Please assess the completion status of the following clinical trial:

Trial Title: Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologic proof of papillary-serous ovarian cancer or 1ary peritoneal carcinomatosis.~2. Histological grade III.~3. Original disease in stage III.~4. ECOG performance status: 0-2.~5. Age: 20-80 years.~6. Previous chemotherapy with paclitaxel and carboplatin (only).~7. Previous cyto-reductive surgery.~8. Clinical Complete Response (both physically and by imaging).~9. CA 125 should be either normalized (in at least 50 patients) or while still in decreasing values at monthly measurements.~10. CBC at normal values or with any toxicity at a grade limited to I by NCIC-CTC.~11. Liver and renal functions \< 1.5 upper normal limits (UNL) by SMA.~12. The patient's signature on the informed consent.~Exclusion Criteria:~1. Mucinous type ovarian carcinoma.~2. Histological Grade I-II.~3. Current continuous treatment by steroids or by NSAIDs, or by anti-coagulants for non protocol reasons.~4. Previous history of active peptic ulcer.~5. Current participation in any other treatment study.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Metronomic Chemoterapy (Type: EXPERIMENTAL): Maintenance Treatment for Ovary Carcinoma by Metronomic Chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).